LLY Stock Recent News

Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on "Bloomberg Open Interest.

Seamus Fernandez, Guggenheim Partners biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest data on Eli Lilly's obesity pill.

AT&T (T) secured a deal worth $23 billion with EchoStar (SATS) to buy spectrum licenses from the company. Eli Lilly (LLY) tacked on billions of dollars in market share after its experimental weight loss pill showed promise in its latest trial results.

Eli Lilly and Co (NYSE:LLY) shares moved higher Tuesday after the company reported positive late-stage trial results for its experimental oral obesity and diabetes drug, orforglipron. The Phase 3 study, known as ATTAIN-2, tested orforglipron in adults with obesity or overweight who also have Type 2 diabetes.

Shares of pharmaceutical giant Eli Lilly and Co (NYSE:LLY) are on the rise today, up 3.7% at $720.07 at last check.

Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.

Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly's weight loss pill orforglipron clearing its latest trial, what it means for the drug going forward, and more.

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.